Table 4 Summary of Gal-3 and Gal-8 in EMT associated with cancer
Galectin | Model | Strategy | EMT Marker | Signaling Pathway | Ref | |
|---|---|---|---|---|---|---|
Loss | Increase | |||||
Gal-3 | Colon cancer cell line (SW480) | Exogenously added | E-cadherin | N-cadherin, vimentin, Twist | N. D | [150] |
HCC cell lines (SMMC 7721, HepG2) | Overexpression, knockdown | E-cadherin | Vimentin | N. D | [182] | |
HCC cell lines (Huh7, Hep3Bm, HepG2, SK-Hep1) | Overexpression, knockdown | N-cadherin, vimentin, MMP-1 | PI3K/AKT/GSK-3β/β-catenin | [175] | ||
Gastrointestinal cancer (AGS and SW-480) | Blockade with LCP | E-cadherin | Vimentin, Snail, Twist, ZEB-1 | N. D | [181] | |
Lung adenocarcinoma cell line (A549) | Exogenous added, blockade with GB117 | E-cadherin | N-cadherin, vimentin | N. D | [185] | |
Oran tongue squamous cell carcinoma cell line (Tca8113) | Overexpression, knockdown | E-cadherin | Vimentin | Wnt/ β -catenin | [149] | |
Breast cancer cell line (MDA-MB-231) | Knockdown | Vimentin, Slug | E-cadherin | N. D | [187] | |
Breast cancer (MCF7), colon cancer (HCT116) and prostate cancer (DU145) cell lines | Exogenous added, blockade with lactose | E-cadherin | ZEB1 | Trop2/β –catenin | [186] | |
Breast cancer cell line (GI-LM2) | Knockdown | E-cadherin | Vimentin | Inhibition of Wnt and AKT pathways | [151] | |
Gal-4 | Prostate cancer cell lines (PC-3, 22Rv1, LNCaP and DU-145) and mice | Knockdown, blockade with lactose | E-cadherin | Fibronectin, vimentin, Twist | ERK, AKT | [152] |
Gal-8 | MDCK cell line | Overexpression, blockade with lactose | E-cadherin | Vimentin, Snail, fibronectin, α5 Integrin, MMP-13 | FAK/EGFR/ERK | [153] |
Primary prostate cancer cell line | Knockdown | E-cadherin | N. D | N. D | [189] | |